보이지 않는 암을 빠르고 정확하게 진단할 수 있습니다.
Practical Utility of Liquid Biopsy for Evaluating Genomic Alterations in Castration-Resistant Prostate Cancer
Traditional tissue-based assessments of genomic alterations in castration-resistant prostate cancer (CRPC) can be challenging.
To evaluate the real-world clinical utility of liquid biopsies for the evaluation of genomic alterations in CRPC, we preemptively collected available plasma samples and archival tissue samples from patients that were being treated for clinically confirmed CRPC.
The cell-free DNA (cfDNA) and tumor tissue DNA were analyzed using the AlphaLiquid®100-HRR panel.
Plasma samples from a total of 87 patients were included in this study.
Somatic mutations from cfDNA were detected in 78 (89.7%) patients, regardless of the presence of overt metastasis or concomitant treatment given at the time of plasma sample collection.
Twenty-three patients were found to have known deleterious somatic or germline mutations in HRR genes from their cfDNA.
Archival tissue samples from 33 (37.9%) patients were available for comparative analysis.
Tissue sequencing was able to yield an NGS result in only 51.5% of the tissue samples.
The general sensitivity of cfDNA for detecting somatic mutations in tissues was 71.8%, but important somatic/germline mutations in HRR genes were found to have a higher concordance (100%).
Liquid biopsies can be a reasonable substitute for tissue biopsies in CRPC patients when evaluating genomic alterations.